Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of oral WJ22096 in advanced solid tumors
CTR20254302Phase 2Active
- Sponsor
- Nanjing Jing'ao Biomedical Technology
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of WJ22096 in Nonhematologic neoplasms, sponsored by Nanjing Jing'ao Biomedical Technology. Started Nov 2025; status: active.
02
Drugs
WJ22096
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20254302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254302.